Protocol Ledger

NCT04572243 · Phase III · TERMINATED

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Interventional Phase III clinical trial protocol NCT04572243 sponsored by Eisai in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-23 Enrollment: 22 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04572243
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)22 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04572243
Protocol FieldVerified Registry Value
NCT IdentifierNCT04572243
Consolidated Lead SponsorEisai
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment22 participants (ACTUAL)
Registered Start Date2020-09-23
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04572243
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI